MGTX - MeiraGTx Holdings plc
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
MGTX price evolution
MGTX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $101.03 | $120.27 | $130.65 | |
| Short term investments | ||||
| Net receivables | $8.43 | $1.63 | $10.91 | $10.14 |
| Inventory | ||||
| Total current assets | $139.05 | $110.77 | $149.3 | $159.62 |
| Long term investments | $6.77 | $6.77 | $6.77 | |
| Property, plant & equipment | $149.43 | $145.95 | $149.93 | $156.24 |
| Goodwill & intangible assets | $0.97 | $1.04 | $1.12 | |
| Total noncurrent assets | $155.88 | $159.94 | $167.12 | |
| Total investments | $6.77 | $6.77 | $6.77 | |
| Total assets | $299.49 | $266.65 | $309.24 | $326.74 |
| Current liabilities | ||||
| Accounts payable | $29.5 | $21.4 | $21.22 | $16.04 |
| Deferred revenue | $57.26 | $57.1 | $36.94 | |
| Short long term debt | $4.21 | $4.19 | $4.19 | |
| Total current liabilities | $59.42 | $47.01 | $47.54 | $67.08 |
| Long term debt | $72.94 | $83.35 | $84.19 | $85.07 |
| Total noncurrent liabilities | $139.61 | $139.96 | $121.49 | |
| Total debt | $87.56 | $88.38 | $89.26 | |
| Total liabilities | $203.75 | $186.61 | $187.5 | $188.57 |
| Shareholders' equity | ||||
| Retained earnings | -$662.62 | -$623.29 | -$574.67 | -$554.23 |
| Other shareholder equity | -$4.85 | -$3.61 | -$3.13 | -$1.44 |
| Total shareholder equity | $80.04 | $121.73 | $138.18 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $130.65 | $115.52 | $137.7 | $209.52 |
| Short term investments | ||||
| Net receivables | $10.14 | $21.33 | $22.38 | $38.48 |
| Inventory | ||||
| Total current assets | $159.62 | $154.34 | $183.24 | $272.58 |
| Long term investments | $6.77 | $6.33 | $6.66 | |
| Property, plant & equipment | $156.24 | $154.09 | $126.29 | $87.12 |
| Goodwill & intangible assets | $1.12 | $1.33 | $1.79 | $2.12 |
| Total noncurrent assets | $167.12 | $163.9 | $136.92 | $91.12 |
| Total investments | $6.77 | $6.33 | $6.66 | |
| Total assets | $326.74 | $318.24 | $320.16 | $363.7 |
| Current liabilities | ||||
| Accounts payable | $16.04 | $16.62 | $15.35 | $7.13 |
| Deferred revenue | $36.94 | $42.56 | $64.87 | $72.84 |
| Short long term debt | $4.19 | $3.88 | $3.37 | $2.58 |
| Total current liabilities | $67.08 | $82.07 | $68.13 | $54.15 |
| Long term debt | $85.07 | $88.36 | $20.36 | $19.67 |
| Total noncurrent liabilities | $121.49 | $118.43 | $66.64 | $70.99 |
| Total debt | $89.26 | $92.25 | $23.73 | $22.25 |
| Total liabilities | $188.57 | $200.5 | $134.76 | $125.14 |
| Shareholders' equity | ||||
| Retained earnings | -$554.23 | -$470.2 | -$340.59 | -$261.03 |
| Other shareholder equity | -$1.44 | $6.05 | -$2.67 | -$4.9 |
| Total shareholder equity | $138.18 | $117.74 | $185.4 | $238.56 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $10.91 | $0.28 | $0.7 | |
| Cost of revenue | ||||
| Gross Profit | -$1.07 | $0.28 | $0.7 | |
| Operating activities | ||||
| Research & development | $34.93 | $34.32 | $33.67 | |
| Selling, general & administrative | $11.26 | $13.15 | $12.12 | |
| Total operating expenses | $38.97 | $46.19 | $47.47 | $45.79 |
| Operating income | -$45.91 | -$46.77 | -$45.79 | |
| Income from continuing operations | ||||
| EBIT | -$45.37 | -$17.19 | $23.66 | |
| Income tax expense | ||||
| Interest expense | $1.34 | $3.25 | $3.25 | $3.45 |
| Net income | ||||
| Net income | -$39.33 | -$48.62 | -$20.44 | $20.21 |
| Income (for common shares) | -$48.62 | -$20.44 | $20.21 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $103.78 | $85.72 | $67.13 | $33.91 |
| Selling, general & administrative | $47.29 | $46.55 | $43.77 | $44.21 |
| Total operating expenses | $151.08 | $132.28 | $110.89 | $78.12 |
| Operating income | -$151.08 | -$132.28 | -$110.89 | -$78.12 |
| Income from continuing operations | ||||
| EBIT | -$70.78 | -$124.67 | -$79.27 | -$57.85 |
| Income tax expense | ||||
| Interest expense | $13.24 | $4.95 | $0.29 | $0.14 |
| Net income | ||||
| Net income | -$84.03 | -$129.62 | -$79.56 | -$57.99 |
| Income (for common shares) | -$84.03 | -$129.62 | -$79.56 | -$57.99 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$48.62 | -$20.44 | $20.21 | |
| Operating activities | ||||
| Depreciation | $3.22 | $3.27 | $3.91 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.81 | $6.96 | $6.96 | |
| Total cash flows from operations | -$19.46 | -$36.74 | -$14.55 | |
| Investing activities | ||||
| Capital expenditures | -$1.33 | $27.34 | $51.18 | |
| Investments | ||||
| Total cash flows from investing | $24.7 | -$1.33 | $27.34 | $51.18 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.61 | $1.59 | $30.01 | |
| Net borrowings | ||||
| Total cash flows from financing | $50.29 | $1.6 | -$1.27 | $27.71 |
| Effect of exchange rate | $0.61 | -$0.06 | $0.29 | $1.9 |
| Change in cash and equivalents | -$5.62 | -$19.18 | -$10.67 | $64.34 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$84.03 | -$129.62 | -$79.56 | -$57.99 |
| Operating activities | ||||
| Depreciation | $13.73 | $8.72 | $7.87 | $4.17 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $27.72 | $28.62 | $20.78 | $18.42 |
| Total cash flows from operations | -$105.36 | -$73.1 | -$10.53 | -$63.97 |
| Investing activities | ||||
| Capital expenditures | $34.03 | -$44.96 | -$55.22 | -$37.02 |
| Investments | ||||
| Total cash flows from investing | $34.03 | -$44.96 | -$61.72 | -$37.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $91.96 | $25.23 | $1.71 | $87.89 |
| Net borrowings | $75 | -$0 | -$0.02 | |
| Total cash flows from financing | $84.02 | $95.2 | $1.71 | $82.73 |
| Effect of exchange rate | $2.44 | $0.67 | -$1.28 | $0.42 |
| Change in cash and equivalents | $12.69 | -$22.86 | -$70.54 | -$18.26 |
News
Fundamentals
| Market cap | $623.89M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 77.70M |
| Revenue | $11.89M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$88.18M |
| Revenue Q/Q | InfinityT% |
| Revenue Y/Y | N/A |
| P/E ratio | -7.08 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 52.48 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.13 |
|---|---|
| ROA | -29.34% |
| ROE | N/A |
| Debt/Equity | 1.36 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.34 |
| Quick ratio | N/A |